A Single Center, Double-blind, Placebo-controlled, Randomized, Phase 1 Study to Evaluate the safety, Tolerability, and Pharmacokinetics of SUVN-D4010 after Single Ascending Doses and Multiple Ascending Doses in Healthy Male Subjects
Latest Information Update: 06 Apr 2021
At a glance
- Drugs Usmarapride (Primary)
- Indications Cognition disorders
- Focus Adverse reactions; First in man
- Sponsors Suven Life Sciences
Most Recent Events
- 31 Mar 2021 Results of early investigations on the safety, tolerability, and pharmacokinetics of SUVN D4010 in healthy young adult and elderly subjects published in the Clinical Drug Investigation
- 20 Jul 2017 Results of two phase I studies including this study presented at the Alzheimer's Association International Conference 2017.
- 03 Jun 2016 Status changed from recruiting to completed.